What the June 2026 study found
Researchers analysed genetic data from over 140,000 patients who had been prescribed GLP-1 receptor agonists for type 2 diabetes or obesity, comparing genetic variants in the GLP-1 receptor gene (GLP1R) against clinical response outcomes — weight loss percentage, HbA1c reduction, and drug discontinuation rates.
The key finding: carriers of specific loss-of-function variants in GLP1R had dramatically blunted responses to semaglutide and liraglutide. In non-carriers, average weight loss was 14-17% over 12 months. In carriers, average weight loss was under 5% — comparable to lifestyle intervention alone. Glycaemic response was similarly diminished.
"We have been prescribing GLP-1 drugs without knowing that roughly 1 in 10 patients is genetically unlikely to respond meaningfully. This is an argument for pharmacogenomic testing before prescribing, not after failure." — Study senior author, June 2026
What is GLP-1 resistance?
GLP-1 (glucagon-like peptide-1) is a hormone released by gut cells after eating. It signals the pancreas to release insulin, slows gastric emptying, and — critically for weight loss — signals the brain's hypothalamus to reduce appetite. GLP-1 drugs mimic this hormone at much higher concentrations than the body naturally produces.
GLP-1 resistance occurs when the receptor the drug needs to bind to — encoded by the GLP1R gene — is structurally altered by genetic variants, reducing binding affinity or downstream signalling. The drug is present, but the lock it needs to turn has a different shape. The result is a blunted biological response despite adequate drug levels in the bloodstream.
How to suspect GLP-1 resistance clinically
Until pharmacogenomic testing becomes commercially available, clinicians should suspect GLP-1 resistance when:
- Weight loss under 5% after 12-16 weeks on the maximum tolerated or target dose
- Minimal HbA1c reduction despite adequate dosing and adherence in T2DM patients
- No appetite suppression reported by the patient — GLP-1 responders almost universally notice reduced hunger within weeks
- Side effect profile is absent — nausea and other GI effects, while unwanted, are pharmacodynamic markers of receptor activation. Complete absence may suggest poor receptor binding.
- Previous failure on a different GLP-1 drug (e.g. liraglutide before semaglutide) without any response
What are the alternatives if Ozempic doesn't work?
Will tirzepatide work if Ozempic didn't?
This is the most important practical question for patients currently failing on GLP-1 drugs. The short answer is: possibly, and it is worth trying before assuming pharmacological weight management is impossible.
Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Because GIP receptor signalling operates through an entirely separate gene pathway (GIPR rather than GLP1R), GLP1R gene variants that blunt GLP-1 response do not affect GIP receptor activation.
In the SURMOUNT clinical trials, tirzepatide produced 20-22% average body weight reduction — the highest efficacy of any approved pharmacotherapy. Early case series suggest some patients who did not respond to semaglutide do respond to tirzepatide, consistent with the dual receptor mechanism. Dedicated trials in GLP-1-resistant patients are currently recruiting.
The broader picture: pharmacogenomics in obesity medicine
This finding is part of a larger shift toward pharmacogenomic-guided prescribing in chronic disease management. The same principle already applies in oncology (BRCA testing before PARP inhibitors), psychiatry (CYP2D6 testing before antidepressants), and cardiology (CYP2C19 testing before clopidogrel).
For obesity medicine, the next logical step is pre-prescription GLP1R genotyping to identify likely non-responders before they spend 12 months on an expensive medication that will not work. Several clinical genomics companies have announced GLP-1 response panels expected to launch in late 2026.
What this means for patients currently on GLP-1 drugs
If you have been taking semaglutide or liraglutide for 3+ months and have seen minimal weight loss despite taking the medication correctly — this research may explain why. Speak with your prescribing clinician about:
- Whether your response has been formally assessed against expected benchmarks
- Whether a switch to tirzepatide is appropriate for your clinical situation
- Whether pharmacogenomic testing is available through your healthcare provider
- What intensive lifestyle interventions could complement or replace pharmacotherapy
Use our BMI Calculator to track your weight loss progress objectively. Our Framingham Risk Score can quantify how your cardiovascular risk changes with weight loss — or doesn't, helping guide decisions about alternative interventions.
Frequently Asked Questions
References
- Nøhr MK, et al. "Loss-of-function variants in GLP1R and differential response to GLP-1 receptor agonists in obesity." Nature Medicine. 2026.
- Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." NEJM. 2022;387(3):205-216.
- Drucker DJ. "The biology of incretin hormones." Cell Metabolism. 2006;3(3):153-165.
- NICE. Semaglutide for managing overweight and obesity TA875. NICE, 2023.